Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/2/2019
SIETES contiene 92666 citas

 
 
 1 a 20 de 211 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Bhupathiraju SN, Grodstein F, Stampfer MJ, Willett WC, Crandall CJ, Shifren JL, Manson JE. Vaginal estrogen use and chronic disease risk in the Nurses' Health Study. Menopause 2018:17 de diciembre. [Ref.ID 102910]
2.Enlace a cita original Cita con resumen
Williams CL, Jones ME, Swerdlow AJ, Botting BJ, Davies MC, Jacobs I, Bunch KJ, Murphy MFG, Sutcliffe AG. Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991-2010: data linkage study including 2.2 million person years of observation. BMJ 2018;362:k2644. [Ref.ID 102818]
3. Cita con resumen
4.Tiene citas relacionadas Cita con resumen
Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV, Thompson CA, Margolis KL, Lewis CE, Stefanick ML, Jackson RD, Johnson KC, Martin LW, Shumaker SA, Espeland MA, Wactawski-Wende J, for the WHI Investigators. Menopausal Hormone therapy and long-term all-cause and cause-specific mortality. The Women’s Health Initiative randomized trials. JAMA 2017;318:927-38. [Ref.ID 102070]
5.Tiene citas relacionadas Cita con resumen
McNeil M. Menopausal hormone therapy. Understanding long-term risks and benefits. JAMA 2017;318:911-3. [Ref.ID 102069]
6. Cita con resumen
Mackenzie IS, Morant SV, Wei L, Thompson AM, MacDonald TM. Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. Br J Clin Pharmacol 2017;83:653-63. [Ref.ID 101935]
7. Cita con resumen
Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncology 2015;16:1061-70. [Ref.ID 99374]
8. Cita con resumen
Nelson HD, Smith MEB, Griffin JC, Fu R. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013;158:604-14. [Ref.ID 95272]
9.Tiene citas relacionadas Cita con resumen
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VHM, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou M-F, Inbar M, Khaled H, Kielanowska J, Kwan W-H, Mathew BS, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R, for the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381:805-16. [Ref.ID 95085]
10.Tiene citas relacionadas
Powles TJ. Extended adjuvant tamoxifen for breast cancer—a new era?. Lancet 2013;381:782-3. [Ref.ID 95080]
11.Enlace a cita original
Urban M, Banks E, Egger S, Canfell K, O'Connell D, Beral V, Sitas F. Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study. PLOS Medicine 2012:marzo. [Ref.ID 92584]
12.
Saso S, Chatterjee J, Georgiou E, Ditri AM, Smith JR, Ghaem-Maghami S. Endometrial cancer. BMJ 2011;343:d3945. [Ref.ID 90959]
13. Cita con resumen
Renehan A, Smith U, Kirkman MS. Linking diabetes and cancer: a consensus on complexity. Lancet 2010;375:2201-2. [Ref.ID 88824]
14.Tiene citas relacionadas
Cummings SR, Thompson J, Eastell R. Lasofoxifene for postmenopausal women with osteoporosis. The authors reply. N Engl J Med 2010;362:2228-9. [Ref.ID 88664]
15.Tiene citas relacionadas
Silva-Fernández L, Andreu J-L. Lasofoxifene for postmenopausal women with osteoporosis. N Engl J Med 2010;362:2228. [Ref.ID 88663]
16.Tiene citas relacionadas
Katzeff BS. Lasofoxifene for postmenopausal women with osteoporosis. N Engl J Med 2010;362:2227-8. [Ref.ID 88662]
17.Tiene citas relacionadas
Malozowski S. Lasofoxifene for postmenopausal women with osteoporosis. N Engl J Med 2010;362:2227. [Ref.ID 88661]
18. Cita con resumen
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: A consensus report. CA: A Cancer Journal for Clinicians 2010;60:207-21. [Ref.ID 88575]
19. Cita con resumen
Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade III JL, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Craig Jordan V, Wolmark N, The National Surgical Adjuvant Breast and Bowel Project. Update of the national surgical adjuvant breast and bowel project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prevention Research 2010;3:696-706. [Ref.ID 88259]
20.Tiene citas relacionadas Cita con resumen
Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R, for the PEARL Study Investigators. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;362:686-96. [Ref.ID 87912]
Seleccionar todas
 
 1 a 20 de 211 siguiente >>